KEY DETAILS
Hims & Hers CEO Andrew Dudum discussed the FTC lawsuit, compounded GLP-1s, and AI with CNBC as regulators examine the company.
Nestle is developing new products, using AI, to reach consumers taking GLP-1 drugs.
Eli Lilly stock has two potential entry points as it gains on Novo Nordisk.
Amylyx stock jumped after avexitide, which blocks the GLP-1 receptor, succeeded in a Phase 3 trial for low blood sugar after gastric bypass surgery.
Andrew Dudum, CEO of Hims & Hers, spoke with CNBC this week about the Federal Trade Commission's lawsuit against the company, along with compounded GLP-1 drugs and artificial intelligence. The interview comes as GLP-1 medications continue to influence decisions well beyond the pharmacy, touching food companies, drugmakers and investors alike. For readers tracking this market, Dudum's comments offer insight into how one of telehealth's more visible leaders is responding to regulatory pressure and industry change.
The FTC's complaint, filed in late July with California and Utah, alleges Hims & Hers shared customers' health information with advertising platforms and made subscriptions hard to cancel. The company denies the allegations, and Dudum used the CNBC interview to lay out its position. He also addressed compounded GLP-1 drugs, which have become a flashpoint as demand for semaglutide and tirzepatide has outpaced supply from brand-name manufacturers. Compounding has allowed some telehealth companies to offer lower-cost alternatives, though it has drawn criticism from Eli Lilly and Novo Nordisk over safety and quality concerns. Dudum's comments on artificial intelligence pointed to how the company plans to use the technology in patient care, a signal that Hims & Hers intends to keep expanding its role in this market even as regulators examine its practices.
Nestle's push into this area reflects a broader shift among food and consumer brands trying to adapt to a customer base that eats differently while on GLP-1 medications. The company is using artificial intelligence and nutritional science to design products aimed at people managing reduced appetite and changed taste preferences, according to reporting on the effort. This is a notable pivot for Nestle, since GLP-1 drugs were initially seen as a threat to packaged food sales rather than an opportunity. If Nestle succeeds, it could set a template for other major food companies watching millions of new GLP-1 users change their shopping habits. For readers who use these medications, this trend may soon mean more products formulated with their specific needs in mind.
Eli Lilly's stock has drawn attention as IBD named it Stock Of The Day, citing two potential entry points as the company gains ground on rival Novo Nordisk. This matters for investors because Eli Lilly and Novo Nordisk remain the two dominant players in the GLP-1 drug market, and shifts in their competitive standing tend to move both stocks. Analysts pointed to Eli Lilly's momentum as a reason to watch these entry points closely, particularly for investors already following the weight-loss drug sector. Readers who hold either stock, or are considering doing so, may want to keep an eye on how this competitive dynamic develops in the coming weeks.
Amylyx shares climbed sharply after the company reported that avexitide, a drug that blocks the GLP-1 receptor, succeeded in a Phase 3 trial aimed at reducing hypoglycemia in patients who had undergone gastric bypass surgery. This is a meaningful result because hypoglycemia after bariatric surgery is a recognized complication, and there have been few effective treatment options for it. A successful Phase 3 trial moves Amylyx closer to a potential approval. Avexitide works the opposite way from drugs like Ozempic: after gastric bypass, too much GLP-1 activity can push blood sugar too low, and avexitide blocks that signal. Investors responded quickly to the news.
These developments make clear that decisions inside boardrooms and regulatory offices are starting to reach directly into how patients manage their treatment and how consumers shop for food. Anyone following the GLP-1 drug market, whether as a patient, investor, or industry watcher, should expect more of this cross-industry activity in the months ahead. And if you hold GLP-1-related stocks, keep watching how competitive shifts between Eli Lilly, Novo Nordisk, and smaller players like Amylyx play out, since those dynamics are moving quickly.
Read this on GLP-1 Nation: https://glp1nation.com/edition/23